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Leading Edge
Highlights of Current Research
Fear of lawsuits may prompt some
doctors to overprescribe antibiotics
Methicillin resistance in Staphylococcus aureus, or
MRSA, is one of the most feared resistant organisms
that clinicians treat given its virulence and ability
to cause infections in a variety of clinical settings.
Its prevalence in hospitals in the United States and
around the world is increasing, conferring severe
consequences on patient morbidity, mortality, utilization of health care resources, and medical care costs.
In a new study led by George Sakoulas, M.D.,
assistant professor of medicine, and four other
NYMC faculty, the authors hypothesized that
medical liability concerns may be playing a role
in the increase of MRSA in healthcare settings by
encouraging clinicians to prescribe antibiotics more
often and more broadly than clinical circumstances
and evidence-based guidelines warrant.
The researchers analyzed census figures, statistics on
attorney and physician densities, and data on antibiotic utilization for the United States, Canada and 15
European countries, to determine the percentage
of methicillin resistance among clinical isolates of S.
aureus. They found a strong correlation between the
prevalence of methicillin resistance and density of
attorneys in countries in Europe and North America. They found no correlation between prevalence
of methicillin resistance and physician density.
Investigators surveyed 162 healthcare providers
to identify that medical liability concerns were as
important as antibiotic cost and formulary
restrictions in selecting treatment regimens. The
surveys also confirmed that physicians were more
concerned about medical liability in cases of
underprescribing antibiotics rather than by
overprescribing them.

The findings suggest that further investigation is
needed to evaluate the potential impact of medical
liability concerns on the medical care system, and hint
toward the importance of medical tort reform as one
way to reduce healthcare costs and improve quality.
One way might be to foster more judicious
prescription of antibiotics based on science and
evidence rather than on risk aversion.
“Relationship Between Population Density
of Attorneys and Prevalence of MethicillinResistant Staphylococcus aureus: Is MedicalLegal Pressure on Physicians a Driving Force
Behind the Development of Antibiotic
Resistance?” American Journal of Therapeutics,
September-October 2009.
Online at http://www.americantherapeutics.com.

Targeting the best delivery point for a
new spinal cord injury treatment
Due to the hazardous nature of combat, war veterans
represent about 22 percent of spinal cord injury
(SCI) cases. While the steroid methylprednisolone is
considered the standard treatment to restore function,
improvement is modest and the treatment is associated with muscle weakness and immunosuppression.
Researchers are seeking new treatments for this
debilitating injury that affects predominantly younger
soldiers with irreversible paralysis.
Before potential new treatments can be studied
with human patients, they must show efficacy in an
appropriate animal model of SCI. Preliminary data
from research led by Richard J. Zeman, Ph.D.,
associate professor of cell biology and anatomy, shows
that targeted stereotactic X-irradiation (SXI) of the
injury site increased locomotor function following SCI.
(continued on page 16)
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(By)passing the Salt
It’s not just stress and diet that can cause
hypertension. Ashok Kumar, Ph.D., and his team
pursue genetic clues in transgenic mice that could
account for almost half the risk.
2
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By Dan Hurley

T

hink you know the causes of hypertension—obesity, too
much dietary salt, psychological stress, obesity and
testosterone? You’re only partly right. Ashok Kumar,

Ph.D., professor of pathology, is quick to point out that lifestyle
factors typically fingered as culprits account for only about half of
the risk related to the disease, which is known to affect some 50
million Americans.
What accounts for the remaining 45 percent of the inter-individual
differences in blood pressure? The answer lies in genetics, a field
in which Dr. Kumar conducts sophisticated research that has lately
garnered him a five-year NIH grant for almost $2 million. Together
with another $2 million grant he received from the NIH three years
ago, the funds assure that Dr. Kumar will continue his exploration
into hypertension’s genetic and molecular basis.
“It has been known for a long time that genetics plays an important
role in hypertension,” Dr. Kumar says. “If parents have increased
blood pressure, there is an increased chance their children will have
it too.” But there is more to it than that, and his two grants focus
on the transcriptional regulation of genes affecting available levels
of angiotensin-II, the molecule that plays a critical role in tightening
blood vessels and thereby raising blood pressure.
Even though two classes of blood-pressure drugs—angiotensinconverting enzyme (ACE) inhibitors and angiotensin-receptor
blockers (ARBs)—targeting the system that Dr. Kumar studies are
already on the market, his research goes deeper, into their genetic
and molecular underpinnings.

From cell culture to in vivo
To understand the role of the AA or AG haplotypes in living organisms, Dr. Kumar’s laboratory generated transgenic mice containing one

After first identifying naturally occurring variants in the genes that

or the other. In doing so, his became the first and, still to this day, the

code for angiotensinogen, the molecular precursor to angiotensin,

only laboratory in the world to develop such mice. The animals were

Dr. Kumar’s team has showed that these single-nucleotide

also given the human version of the gene for renin, which is necessary

polymorphisms, as they are called, form distinct haplotypes

for cleaving human angiotensinogen.

—genetic variations that are usually inherited as a group. He
identified two commonly occurring haplotypes, AA or AG, in a
region that promotes how many copies of the angiotensinogen gene
are transcribed by RNA. The genetic variants have been found to
play an active role in both men and women, as well as in Caucasians,
Japanese and African-Americans.

In a study published in the December 2008 American Journal of
Physiology—Regulatory, Integrative and Comparative Physiology, Dr. Kumar
and colleagues showed that male mice with the AA haplotype had
human angiotensinogen levels that were 60 percent higher in their
livers and 40 percent higher in their kidneys than those with the AG
haplotype. What’s more, levels of angiotensin II circulating in the blood-

“Dr. Kumar has been among the first to look at the genetic

stream of male AA mice were about 50 percent higher than the levels

regulation of the angiotensinogen gene,” said Alberto Nasjletti, M.D.,

in male AG mice, and the first group’s blood pressure averaged 8 mm/

professor of pharmacology and a past president of the Inter-Ameri-

Hg higher. The study was the first to demonstrate in vivo that a genetic

can Society of Hypertension. “We have a number of drugs that can

polymorphism in the promoter of a human gene ultimately leads to an

treat hypertension, but they basically treat the symptoms. Dr. Kumar

increase in blood pressure.

has shown that variations in the angiotensinogen gene may be
playing an important role. It’s an active area of investigation, and
his lab is well recognized in the area.”
The laboratory team of Ashok Kumar, Ph.D. (seated right), is the world’s
first to develop transgenic mice containing human genes that enable the
study of angiotensinogen. Seated to his left is Sudhir Jain, Ph.D., research
assistant professor of pathology. Standing are Varunkumar Pandey, Ph.D.
candidate, and postdoctoral fellows Shreekrishna Maharjan, Ph.D., Andrej
Tillinger, Ph.D., and Brahmaraju Mopidevi, Ph.D.

“Now that we have transgenic mice with human genes in them, these
can be used as a model system.” Dr. Kumar says. “Right now we’re
working with the transgenic animals to try to understand how the
genes are regulated in vivo. Once we know the basic mechanisms, it
will be easier to develop new drugs. Then the mice could be used to
see if a candidate drug is lowering blood pressure or not.”
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“It has been known for a long time
that genetics plays an important
role in hypertension. If parents
have increased blood pressure,
there is an increased chance their
children will have it too.”
– Ashok Kumar, Ph. D.
Sitting behind a desk piled with copies of recent studies—“These are
our lifeline. We have to stay up to date,” he says—Dr. Kumar views with
equanimity a field whose complexity seems to grow more byzantine
with each passing day.

Dr. Kumar’s group began their study of the angiotensinogen gene
and angiotensin receptor gene by conducting association studies
comparing hundreds of people with hypertension to an equal number
of subjects without the disorder. They found strong statistical evidence
that the AA haplotype of the angiotensinogen gene was associated with
higher blood pressure, and that the AG version was associated with
normal blood pressure.
Their next task was to identify the complex molecular steps by which
the two haplotypes orchestrate how much angiotensin II will end up
being produced.
“That part we did in cell culture,” Dr. Kumar says. “And cell culture is fine,
but then we wanted to do it in vivo, in the living organism.”
Now that his pioneering work elucidating the mechanisms behind the
different haplotypes is nearly completed, he says, “We’re mainly
working with the transgenic animals to try to understand how the genes

“It’s a very complicated system,” he says with a smile. “It begins with

are regulated in vivo. We measure their blood pressure all day and night.

angiotensinogen, a protein that is 450 amino acids long and is

We take plasma to measure angiotensin levels. We also take different

synthesized in the liver. Then it’s cleaved by renin, which is synthesized

organs—the liver, kidney and heart—to examine how the genes are

in the kidney, into a peptide 10 amino acids long. Then a third enzyme,

expressed in these tissues.”

angiotensin converting enzyme, converts this into a peptide 8 amino
acids long. This is the biologically active molecule, angiotensin II.”

Of course, the particular genes he’s been focused on are not the only
ones affecting blood pressure. “When it comes to real life,” he says,

Nature, he says, has evolved “a very complicated way to control the

“there are always multiple genes regulating a complex disease like

renin-angiotensin system. And the system has evolved differently

hypertension. We are looking at these other genes now.”

between species. Mouse renin will not cleave human angiotensin.”

Stress, obesity and inflammation
Moreover, he’s looking at the genetic underpinnings of how stress,
obesity and inflammation each play a role in blood pressure. “They may
have completely different genes involved than the ones regulating
angiotensinogen,” he says.
Recent studies have shown, for instance, that interleukin-6 (IL-G), an
immune-system cytokine that plays an important role in mediating
inflammation, increases the expression of the human angiotensinogen
gene in liver cells. In a paper published in the May 2007 American Journal
of Physiology—Cell Physiology, Dr. Kumar and colleagues concluded that
three transcription factors that bind to the human angiotensinogen gene
are responsible for the IL-6 induced promoter activity.
For all the uncertainties that remain, the understanding of essential hypertension has made dramatic advances in recent decades, says John A.
McClung, M.D., associate professor of clinical medicine, in the cardiology
division of the Department of Medicine.
“It was initially called ‘essential hypertension’ because it was necessary for
functioning as people age. If you tried to lower it, you’d kill them,” says Dr.
McClung, who has provided blood samples of hypertensive patients used
in Dr. Kumar’s research. “That’s why guys like Franklin Roosevelt and
Winston Churchill could walk around with blood pressures that would
knock your socks off. It was really only in the 1950s and ’60s that
antihypertensives started to be used with any frequency. Even now,
etiology remains a substantial mystery. That’s why Dr. Kumar’s work is
so interesting—and it’s just beginning.”
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“We have a number of drugs that can treat hypertension, but they basically
treat the symptoms. Dr. Kumar has shown that variations in the
angiotensinogen gene may be playing an important role. It’s an active
area of investigation, and his lab is well recognized in the area.”
– Alberto Nasjletti, M.D.
Dr. Kumar is a Fellow of the American Heart Association’s Council for High

Medical Sciences in New Delhi, he returned to the United States in

Blood Pressure Research, and has served as a member of the Vascular Biology

1979. He continued his research at universities in Texas, Massachusetts

and Hypertension and Microcirculation study sections of the NIH. He has

and Brooklyn, N.Y., before joining the College as a professor in the

also been a reviewer for many prominent journals, including Hypertension, the

department of pathology in 1994, where he has been working ever

American Journal of Hypertension, Human Heredity and others.

since on genes related to hypertension.

Born in the northern Indian city of Rampur, Dr. Kumar conducted his post-

His research into the genetics of hypertension has even struck home.

doctoral research at the University of Wisconsin in the laboratory of H.G.

“My wife Sashi is hypertensive. I am not,” he says. “Six or seven years

Khorana, Ph.D. , winner of the Nobel prize in physiology or medicine in 1968.

ago, I took samples of my blood and her blood, and we analyzed this

Dr. Kumar remained there from 1966 to 1970, working on creating the first

particular genetic variant. We found yes, she has the variant linked to

biologically active synthetic DNA molecule. After serving as assistant

hypertension and I do not. I thought that was interesting.” It sure seems

professor in the department of biochemistry at the All India Institute of

to support his hypotheses. p

Tracking Hypertension Using Genetic Clues

The graph at left shows blood
pressure readings over a 24-hour
period for transgenic mice.The
blue line displays BP readings
from mice with a gene associated
with hypertension, while the red
line shows BP readings from mice
representing “normal” subjects—
those without hypertension.
Blood Pressure Increases in
Transgenic Mice containing
Human Angiotensinogen Gene
Associated with Hypertensive
Subjects
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On the trail of a new
drug to combat deadly
drug-resistant TB
A novel weapon against a global killer may come from
interfering with the ability of the bacteria’s DNA to replicate.
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By Cynthia A. Read

T

uberculosis kills someone every 20 seconds. That’s almost
1,800,000 people a year worldwide, according to the World
Health Organization’s estimate. If you were to invent a

frightening conundrum of a disease, you couldn’t do better than TB.
It is highly contagious and often fatal if untreated, and 98 percent
of the deaths occur among the poorest of the poor in developing
countries. TB does have a cure, but the treatment is a complicated
six-to-nine month, multi-drug regimen developed more than 40
years ago. It is difficult, if not impossible, for many of the sickest
patients to complete.
Combine improper or incomplete treatment, the slow-growing
TB bacteria (Mycobacterium tuberculosis, or M.tb.), and antibiotics in
use since the 1960s, and the upshot is that any TB bacilli that have
developed resistance to a drug multiply easily, until the majority in
the body are resistant. That leads to multidrug-resistant (MDR-)
or extensively drug-resistant (XDR-) TB, which are exponentially
more difficult, time-consuming, and costly to treat—and are more
frequently fatal.
There can be another complication. An estimated one-third of the
40 million people living with HIV/AIDS are also infected with TB,
but the current drug treatment for TB is not compatible with many
antiretroviral therapies for HIV.
A faster, more effective cure for TB would ultimately save millions of
lives, especially if a drug could be developed that killed TB bacteria
in a new way so that people with strains of TB that had developed
resistance to existing drugs could also be treated. This is the goal of
Yuk-Ching Tse-Dinh, Ph.D., professor of biochemistry and
molecular biology. With support from the Global Alliance for TB
Drug Development (TB Alliance) since May 2009, she is studying
whether inhibiting an M.tb. enzyme, topoisomerase I (Topo I), would
kill the bacteria. The researcher is developing methods to identify
Topo I inhibitors, which could then become the basis for new drugs
that could be used against both drug-sensitive and drug-resistant TB.
“One of our goals at the TB Alliance is to stock the TB drug pipeline
with promising and innovative research projects, such as the work
with topoisomerase I inhibitors being conducted in partnership with
Dr. Tse-Dinh’s team,” said Zhenkun Ma, Ph. D., TB Alliance’s chief
scientific officer.
College experts concur. “One-third of the world’s population is
infected with M.tb.,” observes Gary P. Wormser, M.D., director of the
Division of Infectious Diseases and vice chairman for research in the
Department of Medicine. “Drug discovery for TB has been far too
slow and unproductive, and a novel drug to treat TB that is both safe
and effective would be most welcome.”

Yuk-Ching Tse-Dinh, Ph.D., professor of biochemistry and molecular biology,
is investigating the role of an enzyme, topoisomerase I, as a weapon against
Mycobacterium tuberculosis, which has been mounting a distressingly
powerful resistance to the current arsenal of drugs being deployed against it.
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The plates at left and below show type I and type
II topoisomerases, enzymes that assist the
unwinding and rewinding of the DNA spiral. At
left, diagram shows the type I topoisomerase
making a break on one strand of DNA and
passing another single strand through the
break. Below, type II topoisomerases can pass
a double strand of DNA through with breaks in
both strands. Jocelyn E. Krebs, Elliott S. Goldstein,
Stephen T. Kilpatrick, Lewin’s Essential Genes, 2010:
Jones and Bartlett Publishers, Sudbury, Mass. www.
kbpub.com. Reprinted with permission.

“I presented my research results and ideas
to the TB Alliance, and they agreed to work
with us to pursue M.tb. Topo I as a therapeutic
target,” says Dr. Tse Dinh. The need for new
drugs was never more clear to her than when
she heard presentations on the global impact
of TB at a scientific conference at Oxford
University last summer. In countries such as
India and South Africa, where the disease is
rampant, many people with TB cannot afford

antibiotics such as Cipro® disrupt the

the time or money to travel to a distant

function of bacterial type II topoisomerases,

hospital, relying at best on local clinics. The

killing the bacteria.

consequences of faulty treatment and quickly

Dr. Tse-Dinh, who is considered the leading

spreading disease are human and economic

world expert on bacterial Topo I, first

devastation.

became interested in the enzymes that con-

Toward a faster, more effective drug

trol the function of DNA while an undergraduate at Hollins University in Roanoke, Va.
She pursued her Ph.D. in biological chemistry
at Harvard University with James C. Wang,
Ph.D., who discovered the first DNA toposomerase, E. coli Topo I. Since that time she
has focused her research on the structure,
function and regulation of Topo I. In 1988,
she was recruited by Dr. Isidore Danishefsky,
chair of Department of Biochemistry and
Molecular Biology, which was aiming to

Controlling DNA

establish a research laboratory in her field.

For any living cell to divide and multiply, the

“A major research goal of my group,” says

tightly coiled double helix spiral of DNA must

Dr. Tse-Dinh, “is discovering antibacterial

unwind, separate, reproduce, and then rewind.

compounds that work against bacterial Topo

The strands of DNA must also separate to

I.” This would be a first, she claims—no such

allow the synthesis of RNA. Topoisomerases

compounds have been identified by any

are enzymes that facilitate this unwinding and

other researcher. In 2005, Dr. Tse-Dinh and

rewinding by cutting the strand of DNA and

her team demonstrated that bacteria are

then, at the end of the process, connecting it

rapidly killed when they produce mutant

again. Type I topoisomerases, including Topo I,

varieties of Topo I that mimic the effects of

cut one strand of the helix, while type II cuts

inhibiting the enzyme’s ability to rejoin DNA.

both strands. Some well-known antibiotics

They began using M.tb. Topo I as a model

and cancer drugs operate by interfering with

for studying how the enzyme functions, and

the activities of topoisomerases. For example,

she was struck by its therapeutic potential

the broad-spectrum fluoroquinolone

against TB.

“Drug discovery for TB has been far too
slow and unproductive, and a novel drug
to treat TB that is both safe and effective
would be most welcome.”
– Gary P. Wormser, M.D.–
						
8
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Dr. Tse-Dinh and her team are currently
working to develop an automated screening
method that can rapidly sort through tens of
thousands of compounds to detect potential
Topo I inhibitors. These inhibitors will be
evaluated for their effectiveness against the
purified M.tb. Topo I enzyme, using additional
biochemical assays. The research is going
well, and early next year Dr. Tse-Dinh will be
discussing renewal of the partnership with the
TB Alliance, as well as possibly seeking support
from the NIH.

“We have data that indicate treatment with Topo I and Topo II
inhibitors in combination therapy may be synergistic, possibly
					
speeding up treatment.”
– Yuk-Ching Tse-Dinh, Ph. D.
One major benefit of a TB drug based on

TB drug pipeline in the world. Its network

But with the possibility of a Topo I inhibitor drug

inhibiting Topo I would be that the mode of action

of research partners allows for a smooth

showing promise, Dr. Tse-Dinh takes the long

is new, so TB bacteria would not have developed

flow throughout the drug discovery process,

view. Without her years of basic research and

resistance to it. But Dr. Tse-Dinh also believes that

something much appreciated by scientists

studies on the biochemistry of topoisomerase,

such a drug could be faster and more effective

who do not have to assume the burden of

she emphasizes, she would not now be in a

than current drugs. She has shown that when E.

finding the appropriate laboratory or

position to pursue drug discovery. And with

coli bacteria face high temperatures or oxidative

institution to take their research to the next

drug-resistant bacteria a growing problem in

stress, Topo I is involved in turning on the genes

step. In this case, after the Topo I inhibitors

many infectious diseases—think of methicillin-

that respond to this stress. If the same holds true

are identified and validated against the

resistant Staphylococcus aureus (MRSA)

for M.tb., then a Topo I inhibitor would have an

purified enzyme in Dr. Tse-Dinh’s laboratory,

—she hopes her work will inspire researchers

additional method of attacking the deadly bacteria

the TB Alliance could arrange for studying

to explore the potential of bacterial Topo I as a

during the body’s response to infection. Moreover,

the action of the successful inhibitors on the

model target for other diseases.

some quinolone antibiotics, which target Type II

entire M.tb. organism and in animal models

topoisomerase, are already being used as second-

of TB.

line drugs for MDR-TB. Says Dr. Tse-Dinh, “We

TB and beyond

have data that indicate treatment with Topo I and
Topo II inhibitors in combination therapy may be
synergistic, possibly speeding up treatment.”

The journey from molecular and biochemical research to a proven drug takes many
years and billions of dollars, all the more so

Dr. Tse-Dinh had been working closely on this

with a disease like TB, with its torpid bacterial

project with the TB Alliance, which has the largest

growth rate and lengthy treatment protocol.

p

It takes a tough researcher to do battle with drug
resistant TB, and Dr.Tse-Dinh (front and center)
relies on her hardworking team of associates to keep
up the fight. From left are Ph.D. candidates I-Fen
Liu, Gagandeep Narula, Sandra Aedo and Jeanette
Sutherland.To the right of Dr.Tse-Dinh are Jennifer
Becker, research technician, Arasu Annamalai, Ph.D.,
postdoctoral fellow, and Bokun Cheng, M.S.,
research associate.
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The CDC sent Doris Bucher, Ph.D., traces
of a novel influenza virus. In 23 days she
had turned it around for production,
and now the NYMC vaccine is on the
job, shielding the world from the latest
influenza pandemic.
By Marjorie Roberts

College
I
Lab Grows
the First
Seed for
the New
Swine Flu
Vaccine

nfluenza pandemics are the earthquakes of human health. No matter how closely
they are studied, there is no accurate way to predict when they will recur. And there
is no way to prevent the death and destruction that ensue when the Richter scale
trips past five, although proper construction, like vaccination, could mitigate disaster in
both instances.
Each year, the CDC selects strains of seasonal influenza virus for development of vaccine
“seed” strains by a microbiology laboratory at New York Medical College, where the
viruses are reassorted, cloned, amplified and eventually shipped to manufacturers that
supply the entire world population. This seasonal vaccine must be remade each year
because the influenza virus, which annually kills 36,000 in the U.S. alone, has one of the
highest mutation rates of any pathogen. But without warning,
the genome may change, resulting in a virus capable of
producing infection that reaches every population
on earth. Doris Bucher, Ph.D., the
associate professor of microbiology and
immunology who directs the College
laboratory, has spent her 40-year career
studying influenza, preparing for a
pandemic she knew would come. Now
that it has, she fully expects the influenza
vaccine her laboratory has developed—
Novel A(H1N1), still occasionally
referred to as the swine flu—to save
many lives.

10
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Naysayers don’t agree
If only it were that easy. Initial surveys
in the fall indicated that only 50
percent of adults said they
would get the swine flu
vaccine, although 75
percent reported
they intend to take
their children for
the injections
or nasal spray
vaccine.

“It took 23 days to grow the virus and we were the first to do it. The swine flu
seed virus that we made also grew better than seed viruses prepared
by other labs around the world.”
												
– Doris Bucher, Ph. D.

The cheerful team of scientists who populate Doris Bucher’s laboratory appear none the worse for wear after developing the 2009 H1N1 vaccine seed virus to control
the swine flu pandemic in little more than three stressful weeks. But it’s old hat to Dr. Bucher, seated front center, and Barbara Pokorny, lab supervisor, seated left, who
have been working on influenza vaccines their entire careers. Surrounding them are Jianhua Le, Ph.D., research assistant professor; Alex Fulvini, Ph.D. candidate; Shiroh
Onodera, Ph.D., research associate;Yu (Arthur) He, Ph.D. candidate; Jean Marie Silverman, M.S., research technician; Manoj Kumar, Ph.D., D.V.M., research associate, and
Rene Devis, Ph.D., research assistant. Not pictured is Ph.D. candidate Jennifer Arroyo.

In recent years, the seasonal flu shot has
become a high public health priority for
healthcare workers, children, pregnant
women and those over 50. These
recommendations go beyond the original
target populations of the elderly and those
with chronic or life threatening diseases. But
those in targeted groups that have been
expanded through new regulations and
precautionary requirements don’t seem to
be rushing out to be immunized, and the
parameters keep changing for priority in the
swine flu vaccination.
It was 1976 the last time a pandemic was
predicted, and that time it didn’t happen. But
don’t push your luck, Dr. Bucher say. She ticks
off what everyone needs to know about this
year’s swine flu model:
n The seasonal flu shot that has been
available since September is 60 to 80
percent effective in reducing your chance
of getting the flu.

n You cannot get the flu from the injected
vaccine, which is made with a killed virus,
not a live one. The nasal spray relies on a
live virus, and therefore is not recommended for use by pregnant women or children
less than 2 years old. The 1976 swine flu
“epidemic” that never was did result in a
small number of cases with complications
from Guillain Barre syndrome after vaccination, but to this day scientists do not
know why the nervous system disorder
occurred.
n In 2009 one of the greatest risks of complications is for pregnant women, who start
out healthy and then develop pneumonia.
A French research team has recently revealed that in France by October 2009, half
the women who died from complications
were pregnant. Yet there is a reluctance
among pregnant women to get vaccinated
despite the protection it also gives to the
unborn baby. Since the thalidomide disaster

of 1958-61, after which pregnant women
were counseled to avoid pharmaceutical
drugs of any kind, there appears to be some
ambivalence to getting vaccinated, which is
controversial in itself.

How it began
It was a routine workday in April of last year
when Dr. Bucher began reading the ProMED
bulletin she gets every day. The global
electronic reporting system for outbreaks of
emerging infectious diseases and toxins
mentioned the finding of two unique flu
strains around the Texas/California border,
which the CDC was analyzing. The Mexican
epidemic was well underway. Dr. Bucher
immediately emailed several colleagues in
the Influenza Division at the CDC including
Nancy Cox, Ph.D., director, and Alexander
Klimov, Ph.D., chief, and Xiyan Xu, M.D.,
team leader, Virus Surveillance and Diagnosis
Branch, to offer “some really good reagents
for making high yield reassortants. The CDC
CHIRONIAN
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called me and said, ‘Why don’t we send
the virus to you?’” And so Dr. Bucher and
her team were on the job, turning a flu virus
into seed stock—a form of the virus that
will grow rapidly in eggs so that drug
manufacturers can use it to make hundreds
of millions of doses of the vaccine.
She has classified all her seed strains made
on her watch to begin with NYMC “in
honor of the institution,” she says. “It took
23 days to grow the virus and we were the
first to do it. The swine flu seed virus that
we made also grew better than seed viruses
prepared by other labs around the world.
The seasonal flu vaccine we made for 20092010 is called NYMC X-175C. The swine flu
seed is NYMC X179A (a second generation
seed is NYMC X-181). We are definitely
making what’s out there.”
The 2009 swine flu virus has a complicated
genetic history. Influenza viruses have eight
segments, or genetic pieces of the virus. The
2009 swine flu has three segments originating
from American swine flu, two from Eurasian
swine flu, two from avian influenza and one
from human flu. The NYMC swine flu vaccine
seed viruses prepared by reassortment are

attenuated (tamed) viruses with three
segments from the original 2009 swine
flu isolate, and five segments from a virus
isolated in 1934, one that allows the virus to
grow well in eggs, an old fashioned but
reliable medium that Dr. Bucher still prefers.

The master mentor
She learned much of what she knows from
the so-called “father of the flu,” Edwin D.
Kilbourne, M.D., emeritus professor of
microbiology and immunology, who
developed the first genetically engineered
vaccine. Dr. Bucher went to work for Dr.
Kilbourne to develop influenza vaccines at
the department of microbiology he founded
at the Mount Sinai School of Medicine in
New York City. “At the time I had three other
offers,” she recalls, “but Kilbourne’s work
seemed to be the most important—especially
since I had just recovered from an awful case
of the flu! He was interested in my expertise
in developing a vaccine consisting of purified
proteins.” In 1987 she was recruited by the
College’s Department of Microbiology and
Immunology. Five years later she persuaded
Dr. Kilbourne, already elected to the National
Academy of Sciences, to join up, too.
“The flu vaccine manufacturers asked me
if I would keep things going,”
she says, “if and when Dr.
Kilbourne decided to
retire.” That he did in
2002, but he still keeps
a hand in by advising
on all matters of the flu.
In May he was keynote
speaker at the New York
Academy of Sciences
symposium
“Human Swine
Flu (H1N1)
and Novel
Influenza

Pandemics” that Dr. Bucher organized in
New York City.
Anyone glancing through the door window
into Dr. Kilbourne’s lab during his tenure may
remember seeing a woman swathed in white,
seated at the bench with an egg in one hand
and a syringe in the other. She is Barbara
Pokorny, who had been Dr. Kilbourne’s
assistant since he was at Mount Sinai.
Decades later in her current position as lab
supervisor, she is still developing flu
reassortants in those special eggs. “The virus
grows in the cells of the allantoic cavity of
these specific pathogen-free eggs,” Dr. Bucher
advises. “They cost $4.25 an egg and we go
through 30 to 90 eggs a week.”
Others in the Bucher lab include Jianhua Le,
Ph.D., research assistant professor; Jean Marie
Silverman, M.S., research technician; Manoj
Kumar, Ph.D., D.V.M., who performs gene
analysis on reassortants, and Rene Devis,
who assists in gene analysis. The laboratory
is underwritten by IFPMA, a consortium
of influenza vaccine manufacturers with
headquarters in Geneva.

Model of responsibility
Dr. Bucher and her team were slightly
shell-shocked from the crisis and were
extremely tense for months. “We didn’t
know how bad it would be and we wanted
to get this vaccine out to protect the
population. Everyone in the lab was feeling
intense pressure,” she says. Having been the
department course director of medical
microbiology for 14 years, she perhaps
handled the stress better than the others.
“The virus is always changing and always a
challenge. There is no other vaccine that is
changed every year,” she states. “Once we
were successful in developing the virus
reassortant seed, we continued to improve
the virus, resulting in a second generation
seed that grew twice as well as the original.”
With her time of crisis passed, Dr. Bucher
can only hope that the vaccine manufacturers will be able to increase the H1N1
supply to match the demand, whatever that
ultimately turns out to be. Not that she can
ever stop worrying about the flu altogether.
Her lab has already started the process that
will produce the seed for the 2010 seasonal
influenza vaccine.p
Lab supervisor Barbara Pokorny has been injecting
eggs with flu viruses since the 1970s, working first
with Dr. Edwin Kilbourne and continuing with Dr.
Doris Bucher.The entire team felt the pressure last
summer while pandemic fears mounted and the
world awaited a viable vaccine.
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Albert B.
Lowenfels, M.D.,
IS GOING STRONG at 82
Surgeon, teacher and researcher, he
is currently P.I. for two epidemiology
studies. Ready to retire? “Maybe”
By Marjorie Roberts

T

o all appearances, Al Lowenfels is a soft spoken gentleman of
few words and cares. That may be true, but in the 82nd year of
his life, when most his age have long been retired to indulge in
pleasant pastimes and playing with their grandchildren, Albert B.
Lowenfels, M.D., is still doing what he’s always done. One of the first
things he does at least one day a week is to walk seven miles roundtrip
to the New York Medical College campus from his home in Thornwood.
He prefers to make the return trip while it is still light outside because
“I have to pass through two graveyards,” he says with a twinkle in
his eye.
Once he is settled in the fifth-floor cubicle in Munger Pavilion that he
built himself over one weekend, he methodically turns to the issues that
induced him to stop practicing general surgery 19 years ago. Teaching
and research had captured his fancy, while the liver and pancreas, and
the disease of alcoholism, became the objects of his most devoted
intentions. Indeed, in his built-in office, which is as tight and efficient as
a ship’s stateroom, Dr. Lowenfels is the proverbial happy clam. The
cabinets, pullouts and drawers, holding the repository of his life, are
all he needs to work and continue to thrive.

No loss for words
When he speaks there is no searching for a word, no lapse of memory,
no matter how long ago the incident took place. So it goes for a major
medical conference he conceived a decade ago to celebrate the turn
of the century—an event that turned out to be a smash hit and
positioned the College as the region’s biomedical academic
powerhouse. It was his idea to have eight illustrious scientists come
and lecture to New York Medical College students, who were excused
from classes for the day.
“I wrote a note to everyone [I invited] and said, ‘Would you like to
come to our millennium conference?’ It didn’t say anything about
compensation, yet everyone said yes. I was surprised,” he admits.
“Medicine at the Millennium” was held at a large performance hall
at a neighboring undergraduate university to accommodate all
CHIRONIAN • New York Medical College
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the students, faculty and guests who came to hear the likes
of Luc Montagnier, M.D., co-discoverer of the virus that causes
AIDS, and David A. Kessler, M.D., J.D., dean of the Yale University
School of Medicine and former commissioner of the Food and
Drug Administration.

Need an idea?
Reinhard E. Zachrau, M.D., is professor of pathology at the College
and the course director of pathology/pathophysiology, which runs
the entire second year. He can attest to the original ideas that Dr.
Lowenfels emits with ease, citing the Historical Clinical-Pathological
Conference that is part of his course. A third-year student discusses
the clinical aspects of a case concerning a person famous in a
previous century, presenting the findings to the entire second-year
class. James Joyce was dissected last year in the day-long event that
evinces the progress made in treatment between the subject’s
century and this one.
“It was Lowenfels’ idea and I jumped on it,” says Dr. Zachrau. “He
has a researcher’s mind. He’s known internationally. And he is very
interested in education.” Perhaps his grammar school experience
primed him to make education an important part of his life. With
a brief shake of his head, Dr. Lowenfels reveals that from
kindergarten to fourth grade he attended a one-room schoolhouse
in the Rosedale section of White Plains, N.Y. “I had 12 in my first
grade class and only one in the fourth grade. We were lucky to
have a blackboard!”

“He has a researcher’s mind. He’s
known internationally. And he is
very interested in education.”
– Reinhard E. Zachrau, M.D.
			
Interests change
A native of New Rochelle, N.Y., Dr. Lowenfels received a B.S. in
chemistry from the University of Vermont, and his M.D. from the
New York University School of Medicine. He interned and did his
surgical residency at Bellevue Hospital, opening a private surgical
practice in 1959 that “was mostly abdominal,” he says. “I always had
a lot of patients with ruptured spleens. We had to make a diagnosis
without the benefit of a CT-scan. A few of us put together a report
on what we had learned—to put a patient flat on the back, with the
knees pulled up. After tilting the table, any blood there would cause
pain to be referred to the left shoulder.
“This turned into a study of five or six patients, which I wrote up
and sent to the New England Journal of Medicine. This was my first
paper in the NEJM. I was still in private practice, but the experience
made me decide it was much more exciting to be teaching and
doing research…It was too bad I had majored in chemistry before
there was DNA. I might have stayed with chemistry but there were
no role models.” What he did do was join Westchester County
Medical Center, where he became associate director of surgery in
1966, and director of surgical research in the Department of
Surgery at the College one year later.
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Success turns his head
“Westchester was a rough and ready place when I first came here,” he
says with a grin.
The College made him a full professor of surgery in 1979, and two
years later tapped him as professor of community and preventive
medicine. Dr. Lowenfels taught medical students in every year of
undergraduate and graduate studies, plus master of public health
candidates in the Graduate School of Health Sciences, now the School
of Health Sciences and Practice. The stunning range of topics he has
taught includes biostatistics and epidemiology, surgical diagnosis and the
history of medicine.
Through the years Dr. Lowenfels took on other assignments, such as
director of surgery at Westchester Community Health Plan, an HMO,

“I’m not worried
about death.
I just don’t want
to be there when
it happens.”
– Albert B. Lowenfels, M.D.,
quoting Woody Allen

and a stint at the International Agency for Research on Cancer.
He found himself gravitating more to research, having decided “there is
not much difference between research and teaching. Research is
discovering things and teaching is helping others learn through
discovery.” He proceeded to reinvent himself into a scientist who
succeeded in having 18 articles printed in the New England Journal of
Medicine alone.
Since 1966, the Christopher D. Smithers Foundation, Inc. has given Dr.
Lowenfels and the College nearly $1 million in grants. Many of the
studies were centered on the pancreas as he investigated the
epidemiology of alcohol-induced acute and chronic pancreatitis and
cancer. In 1985 Solvay Pharmaceuticals, which recently became part of
Abbott Laboratories, began funding his unrestricted research on
pancreatic disorders and his reputation grew as an expert on one of

the deadliest of all cancers. Still, he investigated whatever interested him,
such as the large study he led on the risk of cancer among patients with
cystic fibrosis. He presently has two active projects—the relation of the
ABO blood groups to pancreatic cancer, and the link between the growth
rate of polyps to colorectal cancer. He projects another year to finish
these studies, and then, who knows?
With a “young wife” of 81, four children and a grandson who is in his
second year of medical school, Al Lowenfels is living every day his way;
last August he went on a walking tour of Ireland. When he is pressed to
say something salient about life, death or the future, he prefers to quote
Woody Allen: “I’m not worried about death. I just don’t want to be there
when it happens.” p
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Leading Edge
(continued from inside front cover)
The team conducted a trial on SCIinduced rats to determine the proper
location and optimal target volume of SXI
to improve functional recovery. Because
of the precision of SXI, researchers also
wanted to determine the optimal region
of administration to produce the most
effective response in the rats’ rehabilitation.
SXI was administered 20 minutes
following the injury with a radiation beam
centered on or close to the injury site.
The team evaluated SXI efficacy on
motion recovery, using a locomotor scale,
by examining spinal cord function six
weeks following treatment of the injury.
The greatest increase in locomotor
recovery was observed with SXI
centered at 4-mm rostral to (above)
the point of the injury. This location also
resulted in the greatest level of tissue
sparing following the procedure.
The authors concluded that their results
indicate that SXI in a region several
millimeters rostral to the injury is most
critical for locomotor recovery, and that
optimizing this treatment may lead to
a therapeutic modality for spinal cord
injuries suitable for use in battlefield
conditions.
“Optimal Therapeutic Target
for Stereotactic X-irradiation in
Experimental Spinal Cord Injury.”
Paper presented at the Military Health
Research Forum, a scientific meeting
hosted by the Department of Defense
Congressionally Directed Medical
Research Programs, on Sept. 1, 2009.

Midlife weight gain in some
women may be caused by
insulin resistance
Progressive weight gain that starts in the
fourth and fifth decades is commonly
reported by women from all ethnic and
socio-economic groups. Current data
suggest that, in large and diverse subpopulations of healthy-appearing women,
this midlife weight gain may represent the
earliest clinical manifestation of insulin
resistance, evidenced by increased insulin
response curves in the presence of
normal glucose tolerance tests.
Harriette R. Mogul, M.D., M.P.H.,
associate professor of clinical medicine
and Director of Research in the Division
of Endocrinology, coined the term
Syndrome W to highlight its defining triad
(continued on page 32)
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JANUARY
16th Annual Author
Recognition Sherry

Dean’s Research Award
and Lecture

Health Sciences Library

Medical Education Center
Nevins Auditorium

Tuesday, January 12

Thursday, January 21

FEBRUARY
Medical Student Research Forum
Medical Education Center
Nevins Auditorium
Thursday, February 4

MARCH
Match Day

Alpha Omega Alpha Visiting
Professor Lecture

Medical Education Center
Atrium Lobby

Medical Education Center,
Nevins Auditorium

Thursday, March 18

Wednesday, March 24

APRIL
National Public Health Week

Graduate Student
Research Forum

School of Health Sciences
and Practice

Medical Education Center

April 4-9

Wednesday, April 7

Student Physician Awareness Day
Maria Fareri Children’s Hospital
at Westchester Medical Center
Thursday, April 22

MAY
Alumni Reunion Banquet

Alumni Reunion Luncheon

Sheraton Hotel and Towers
New York City

Valhalla Campus
Sunday, May 23

Saturday, May 22
151st Commencement
Carnegie Hall
New York City
Wednesday, May 26

✁
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Calendar of Events
for 2010

Support New York Medical College
This year, as we begin celebrating the College’s 150th anniversary, we invite you to join the many benefactors who
are working to maintain the College’s tradition of excellence in the 21st century by investing in the Annual Fund.
Expand Educational Opportunities
Each year, our students assume an increasingly heavy financial burden as the cost of a first-rate health sciences education skyrockets.
Your gift will strengthen our tradition of reducing financial barriers for many talented and deserving students.
Enhance Academic Leadership
New York Medical College boasts some of the brightest minds working in health sciences education and research today.
Your gift will provide the resources needed to continue to develop this stellar academic team.
Transform Medical Education
Having access to the latest tools and technologies is essential for training top-flight professionals.
Your gift will prepare tomorrow’s healthcare professionals for the challenges and opportunities of 21st century medicine.
Invest in Campus Infrastructure
The resounding success of the Medical Education Center and recently renovated Basic Sciences Building lobby demonstrates the
key role that beautiful and innovative facilities play in creating a desirable academic environment. Your gift will help to improve and
maintain campus facilities at a competitive level.

Please make a gift today. Your support could have an extraordinary impact on the College’s future.

✁
READER SURVEY
In our last issue of Chironian, we ran the following survey of habits, tastes and preferences of you, our readers.
Your responses were very enlightening, and will be used to improve the magazine and give you more of what you
like to see in the magazine. We are extending our response deadline for the Chironian Reader Survey, and adding an
online option so we can incorporate even more of your responses into our editorial planning. If you’d like to
complete your survey online, go to http://www.surveymonkey.com/s/TJFGFDL
1. Why do you read Chironian? (Rank in order of importance)
______ News about alumni
______ News about the College, its activities and progress
______ News about students, faculty, leadership
______ Trends in research and medical education

3. Please rate how much you agree or disagree with the
following statements:
Strongly
Neutral		
Disagree				
1

2

3

Strongly
Agree
4

5

______ The “State of the University”

The articles are interesting and informative____________

______ Other ____________________________

The layout and design make it easy to read ___________

2. How much of each issue do you read?

The magazine keeps me up to date on alumni _________

______Read it cover to cover

The magazine keeps me informed about College
current events and the state of the University__________

______Read or skim about half the articles
______Read only what interests me
______Read only about people I know
______Don’t read it

The magazine is one way to learn about trends in
research and medical education ____________________
The articles provide a good balance of the technical
and the personal ________________________________
(continued on reverse)
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(continued from other side)

4. Please rank from 1 to 5 which sections of Chironian
interest you the most (1= most interest, 5= least interest)
______Research articles		

______University news

______Personality profiles

______Student features

______Alumni news		

______Milestones

6. What other topics or features would you like to see in
Chironian?
_________________________________________________
_________________________________________________
7. Which best describes your relationship to New York
Medical College?

5. On a scale of 1 to 5 (1= very well, 5= not well at all) rank
each of the following for how well Chironian keeps you
informed about:

__Alumni (Circle: Medicine, Basic Sciences, Public Health)

______News about alumni

__Staff

______News about the College, its activities and
accomplishments

__Campus or facility (Circle: Main, WMC, SVCMC, Met, Other)

______News about students, faculty, or leadership
______Trends in research and medical education

__Faculty (Circle: Full-time, Part-Time, Voluntary)
__Student (Circle: Medicine, Basic Sciences, Public Health)

8. Comments
_________________________________________________
_________________________________________________

______The “State of the University”

_________________________________________________

______Other _____________________________________

_________________________________________________
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Respond to the Chironian Reader Survey today and let your voice be heard!

Students
Revering the
Human Spirit
Students learn much more than the
physical structure of the human body in
their first-year gross anatomy course.
They also learn about respect, dignity
and the gift of being human.
By Andrea Kott, M.P.H.

W

hat defines us, making us uniquely human and distinct
from one another? For some, it is the intangible: our
ability to reason, our capacity for empathy, our soul.
For second-year medical students Bridget Oliveri and James Naples,
it is also the physical: hands, feet and faces.
It has been a year since Oliveri and Naples first entered
the Alumni Gross Anatomy Laboratory and met their
“first patients”—human cadavers whose dissection
provided their introduction to the human body. It
is a hallmark event in the life of a medical student,
one that conjures a little nervousness and fear, as
well as fascination. Oliveri and Naples anticipated
those emotions. What they did not foresee in the
end was a personal connection to the cadavers
and, ultimately, a sense of their humanity.
In the beginning there was some anxiety or, as
Oliveri describes it, “a weird mix of excitement
and trepidation.” She recalls “the rush” leading
up to orientation, when students—who work
together in groups of four—meet each other
and observe as assisting upperclassmen remove
the shrouds that cover the cadavers. “They pull
back the cloth and we meet the body for the
first time,” Oliveri says. She recalls thinking, ‘I’m
really excited, but am I going to be the one
who faints?’”
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“People assume that to train medical students
you have to teach them to distance and separate
themselves, that the patient is just an entity. But
[students] readily recognize the fact that this person
still has dignity that must be respected.
-Matthew A. Pravetz, O.F.M., Ph.D. ’88
(continued from previous page)

Neither she nor Naples fainted. In fact, Matthew A. Pravetz, O.F.M., Ph.D. ’88, associate professor of cell biology
and anatomy who, as director of the anatomy course, has taught the class—each comprising approximately
195 incoming medical students—since 1989, paces the reveal gradually and sensitively so students have time
to adjust.
“We spend time getting acclimated to the whole idea that this is what we’re going to be doing for the next
few months,” Oliveri says.
After orientation, however, things pick up and by day 7 students are removing
and holding cadavers’ organs. “It didn’t feel like we were doing it for that long
and we were already holding the person’s heart in our hands,” Oliveri recalls,
sounding amazed, still.

Learning landmarks
Dr. Pravetz calls certain milestones, like holding a heart, “epiphany events.” It
is especially telling, he says, that students recall them so vividly, a year or more
later. “There are certain key times during the course that are so revealing to
students,” he says. “When they see the heart in the chest where it should be
and then when they actually take it out and hold it in their hands, everything
gets kind of hushed in the room.”
Another epiphany experience is removing the brain, such an essential part of
a person’s personality, life and memories, and making their first incision is yet
another moment never to be treated lightly. Dr. Pravetz explains, “As you can
imagine, there is a lot of anxiety and tension.” There is also a tremendous
sense of awe.
“We treat it very reverently,” he says. “We don’t just say cavalierly, ‘Pick up
the scalpel and give it a cut.’ We look at the whole person. We examine
the area. We take the knife and gently and reverently make the first
cut.” It is a vertical incision in the chest, and although the blade cuts
through less than one-quarter inch of skin, it typically takes students
10 minutes to complete. He says. “They do it with great respect.”
The 14-week course is divided according to the parts of the body
to be dissected—first the chest, then the abdomen/pelvis, then the
extremities: arms, legs, head and neck. “By the end of the second
week we have lungs in our hands,” Dr. Pravetz says. By the end of
the fourth week, the students are holding kidneys. In the seventh
week they uncover the cadavers’ hands and in the ninth week,
the feet. Not until week 10 do they see the face.
There is a reason for this timing. The hands, feet and face
are a person’s ultimate signature. Their exposure puts an
end to any dispassion or emotional distance the students
may have managed to maintain and reminds them, often
unexpectedly, of their own humanity.
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“You see rough hands, smooth hands, bruised hands, calloused hands,
manicured hands. One hand might have a little bit of nail polish on
it,” Dr. Pravetz says. “All of a sudden it brings back the person.”

The face makes us human
Once the face is exposed, the entire feeling in the room changes.
“All of a sudden things come to a stop,” Dr. Pravetz says. “Now it’s
not just students looking at a cadaver’s hands. Now they have a faceto-face encounter with that individual they’ve had the privilege of
studying up to that point. All of this packs an emotional wallop.”
Indeed, seeing the face of his cadaver changed what had been a
purely academic exercise into a personally spiritual experience for
Naples. “Before you see the face you’re dealing with the body and it’s
easy to distance yourself,” he says. “But when you see the face, that’s
when it becomes real.”
This empathy and concern for their first patient’s well-being is
precisely what Dr. Pravetz is after. It is, after all, what sets the stage
for the rest of the students’ medical training. “There seems to be an
assumption that to train medical students you have to teach them to
distance and separate themselves, that the patient is just an entity,”
he says. “But students readily recognize the fact that this person still
has dignity that must be respected.”
That respect becomes evident in the caring, almost protective way in
which the students relate to the bodies, Dr. Pravetz says. “I see out of
the corner of my eye how they carefully wrap the person up or how
gently they turn the body over,” he says. It does not surprise him that
students bond with their cadavers.

“You get pretty attached to your own person,” says Oliveri, who named her
cadaver Bernie. “Throughout the lab, I kept realizing that I was holding his
hand, almost subconsciously. I think it was a little comforting for me—and
somehow for him.”
When Naples looks back on the year he spent in gross anatomy, he
marvels over the generosity of the individuals who donated their bodies:
“It is so amazing that people get to the point where they’re willing to do
that. It makes me realize how fortunate I am as a student.”

Giving thanks
The students’ gratitude to the donors and the donors’ families is profound,
and each spring they have the opportunity to express their feelings in a
ceremony called the Convocation of Thanks. The ceremony, a memorial
service of sorts, is student-created, comprising the recitation of original
poems, reflections, and musical compositions that students perform in an
attempt to convey their heartfelt appreciation. After the performances,
which are held in the Nevins Auditorium before a capacity audience
each year, the convocation moves outside for the ceremonial planting of
a young tree in honor of the individuals whose donations of their bodies
make the program possible.
The Convocation of Thanks does more than give students the chance to
articulate their gratitude. It encourages them to reflect on what they have
learned as budding physicians and, more important, to connect the
educational with the emotional.
“It is difficult to take at face value Gross Anatomy as an educational tool
without being in touch with the emotional and spiritual side of it,” Naples
says. “Both are important in helping us develop as future doctors.” p
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Keeping the Faith
For a doctor who is also an ordained minister, practicing
medicine means healing body, soul and society.
By Melissa F. Pheterson
and cystic fibrosis. “When a child looked up at me and asked, ‘Am I
going to die today?’ it tore my heart out, and reminded me that I had
to keep fighting for these patients,” she says.
A fellowship at Mount Sinai Medical Center after her residency
placed Dr. Perez in the vanguard of adolescent medicine, then a
fledgling specialty. “This new idea that children could see their
health provider alone, no parents in the room, was super spooky,”
she says. “Doctors were just arriving at the concept of teenagers
as individuals.”

Photo by Jose A. Rios

In the early 1980s, Dr. Perez served as attending physician at
Gouverneur Hospital in Manhattan, where she treated adolescents
from a range of backgrounds: Asian, Latino, African-American.
“I realized that to become a better doctor, I had to get rid of my
personal biases,” she says. “Underneath their different skin tones
and modes of dress, all my patients struggled with the same
emotions: stress, anxiety and the temptation to rebel.”

Dr. Lucy Perez has the youthful vigor—and appearance—of a woman many
years younger. Her passion for doing right by people impels her to take on
challenges that ordinary folks might find daunting. Her six-year-old son JayCee
came into her life on the wings of such a challenge.

As a consultant for New York City’s Department of Health, Dr.
Perez developed several programs for teenagers to address
substance abuse, HIV/AIDS and pregnancy, including a “Teens and
Tots” group for adolescent parents. She also helped start the city’s
first school-based clinics, noting firsthand the violence that plagued
the public education system in poor neighborhoods.

In the minority

A

A growing awareness of the cards stacked against minorities
inspired Dr. Perez to found the Cave Institute, a venture committed
to eliminating health care disparities through research, ethics and
advocacy. Cave was her mother’s maiden name, and that of her
medical family of three doctors, a registered nurse and a medical
librarian. The family tradition and values are carried on by her
daughter Nikki, 25, now a third-year medical student at Howard
University who aspires to a career in orthopedic surgery.

“Both my parents died at 61,” recalls Dr. Perez, a resident of
Bethesda, Md., who has kept her Brooklyn accent. “My mother was
a diabetic with chronic renal failure, blind and an amputee when
she died—and she was a registered nurse!”

Through Cave, Dr. Perez conducted surveys of faculty at historically
black colleges and universities, highlighting pay and funding
disparities in comparison with similar white institutions. She also
brought clergy into discussions, noting that “faith leaders exert
a significant influence on beliefs and attitudes in communities
of color.” Above all, she has tried to instill awareness among
minorities of the obstacles that hamstring their lives.

s a physician, Lucille Norville Perez, M.D. ’79, labors to
heal broken bodies. As a minister, she tends to broken
spirits with the same compassion and skill she brings
to doctoring. And in trying to close the gap in access to
affordable health care that persists between whites and minorities,
she invokes herself as an example, a casualty of an unjust medical
hierarchy.

For Dr. Perez, who once served as national health director of the
NAACP, mending healthcare disparities begins with instilling a sense
of empowerment to vulnerable patients, whether they’re battling
chronic illness or entrenched poverty. Her passion for the task goes
back many years to when she was a pediatric resident at Long Island
Jewish Medical Center, where she treated children with leukemia
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When her older son Juan Carlos, now 30, was growing up, Dr.
Perez showed him the neighborhoods of Park Slope, an affluent
white enclave of Brooklyn, and Flatbush, a poorer minority section.

The contrast between the manicured gardens of the
former and trash-ridden streets of the latter prompted
him to ask his mother why blacks “don’t get rid of
their garbage.” She asked him to count the garbage
cans they saw in each district. “In Park Slope, there
was one next to every bench. In Flatbush, we went
blocks before we saw one,” Dr. Perez says. “We must
make clear to our children: ‘This is not my culture, this
is not my fault. This is political oppression, unfair and
unjust. And I don’t have to accept it.’ This way, they’re
not paralyzed, but empowered.”
After Hurricane Katrina left poor Gulf residents
strapped for basic health services, Dr. Perez formed
a coalition to provide emergency health care. She
worked with the sitting presidents of black health
professional advocacy organizations, and a host of civil
and human rights groups. She tapped as her adviser
Phyllis Harrison-Ross, Ph.D., professor emeritus of
psychiatry, who taught her when she was a medical
student. “In the autumn of my career, she’s again
instructing me,” says Dr. Perez. A subcommittee of this
coalition still meets twice a month to provide mental
health services that to this day are still inadequate.
Since 2006 Dr. Perez has been the national medical
director for UPRIS, a Cleveland-based company that
specializes in health information technology delivered
in a culturally appropriate manner to promote health
literacy in patients. The African Methodist Episcopal
Church (AMEC) uses UPRIS portals, with patient
consent, to monitor the health of more than 6 million
congregants. Health information, including culturally
appropriate prevention messages, can be disseminated
to congregants via a trusted AMEC portal.

Faith calls
Such ventures spring from Dr. Perez’s intense faith in
humanity to work toward repairing the world, perhaps
inspired, as she is, by ardent religious beliefs. Her
outgoing voice mail message proclaims: God is good,
and he loves you. “I believe we are spirits having a
bodily experience,” says Dr. Perez, who in 2002 was
ordained in the African Methodist Episcopal Church
while serving as the 102nd president of the National
Medical Association. In 2006 she adopted the son of
a family friend struggling with mental illness. “I was
asked to watch little JayCee for four days,” she says,
“and in December it will be three years.”

“You could be wasting resources on drugs, therapy or
interventions that are not heeded, because they clash
with someone’s belief system,” she says. “So if I don’t
explore deeper to tap that belief system, I haven’t led
you to a path of healing.”p
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To Dr. Perez, the spiritual beliefs of a patient—how
often he attends church, his sense of something
greater than himself—should carry the same weight as
smoking habits or family history in a medical exam.
Belief and faith are crucial to healing, she says, and
“invaluable to the practice of medicine.”

Lucille Norville Perez, M.D. ’79
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Through hard work
and compassion
for health care
rights, a nurse
transforms from
“on staff” to “in
charge.”
By L.A. McKeown

I

t’s late afternoon on a chilly October
day and Judith M. Watson, M.P.H. ’07,
still hasn’t had lunch. Between
meeting with representatives from a
local hospital, dealing with staff issues,
returning emails and telephone calls,
working on applications for funding,
preparing a report for the center’s
governing board and speaking with a
reporter, her day as executive director of
the Greenburgh Health Center in White
Plains, N.Y., has been full, to say the least.
“It’s crazy, but I love it,” Watson says. “I’m
one of those rare people who love what I
do. I love waking up and going to work in
the morning.”
When Watson first walked through the
doors of Greenburgh in 1994, she was a
newly-licensed RN who felt she already
had exceeded her own expectations. She
had overcome a number of challenges in
her early years and says she was not a
typical student. After eight years at
Greenburgh she was offered the executive
director position, which she accepted—
along with a whole new set of challenges.
“I’m very fortunate, but my getting this
position is mostly the result of just plain
hard work,” she says. Watson credits
her mentor and boss, Carole Morris, with
helping her achieve her goals and
encouraging her to believe in herself.
Morris, who is the chief executive officer
of the Mount Vernon Neighborhood Health
Center Network, of which the Greenburgh
center is a part, recognized the ambition and
passion in Watson and offered support and
guidance as she rose through the ranks, one
position at a time.

Judith M. Watson, M.P.H. ’07

Statuesque and upbeat, Judith Watson directs a
neighborhood health center that revolves around the
radical idea that health care is a fundamental right of
every human being, regardless of their ability to pay.

“I have worked in each and every department in this health center,” Watson says with a laugh. “I have a strong work ethic and I
became that person who would do whatever was asked of her,
whatever needed to be done at that moment in time.” Watson
also credits her three years of active duty in the U.S. Army and
four more in the Reserves with helping her achieve a “stick with
it” attitude and hone much-needed organizational skills.

Legacy of Community
As a satellite site of the Mount Vernon Neighborhood Health
Center Network, the Greenburgh Health Center is one of the
nation’s 5,000 Federally Qualified Health Centers, or FQHCs.
The center offers comprehensive, affordable primary health care
services to its patients, about half of whom are uninsured and
undocumented.
“We provide primary health care services regardless of ability
to pay,” Watson says. “The fee to see a provider is based on a
sliding scale, but we don’t turn anyone away based on ability or
inability to pay. Even if they come in with no money on them,
they would still be able to see a doctor that day.” Due to
widespread economic woes, Greenburgh has become
particularly important for many people in the area who have lost
jobs, and lost insurance, according to Watson. The center also
accepts patients regardless of immigration status, a policy that
many health care providers would prefer to avoid.
The Greenburgh center offers everything from pediatrics to
internal medicine, along with dentistry and ophthalmology all
under one roof. It also has its own lab to serve the more than
19,000 registered patients who make 92,000 annual visits to the
center each year. Watson supervises a staff of 88, including
providers, nurses, medical assistants and clerical staff.

Going further, wanting more
Getting the top spot was a major career achievement for Watson, who
was only 34 years old at the time, but she didn’t stop there. “Once I
was sitting in this seat I realized I needed to go back to school and get
my masters degree,” she says. So, at the urging of several colleagues,
including Vice Dean James O’Brien, Ph.D., who served with her on a
community board, she enrolled in the Master of Public Health program
at New York Medical College’s School of Public Health (now called the
School of Health Sciences and Practice).
Watson’s graduating class was the pilot group for the capstone
course, a culminating experience that offers a hands-on alternative
to a thesis. Students are given an in-depth understanding of
current and emerging areas of critical interest through the analysis
of actual cases from the annals of public health practice. Watson
says she was glad to opt for this alternative route to her degree.
Today, she feels having gone through the Health Policy and
Management track helped inform and broaden her views on the
national health care debate.

Expansion and frustration
The need for community health centers is continually growing.
Under the direction of her CEO Carole Morris, Watson has led
Greenburgh in attempting an expansion project that would move
them to a new, larger building and more than triple their
functional space from 13,000 to 40,000 square feet. But the project
has been fraught with obstacles, mainly due to members of the
community who have objected to having a health center in their
neighborhood, and who managed to stall the project for 5 years.
By the time the approvals came, the budget had doubled from $10
million to a nearly unattainable $20 million.
(continued on page 29)
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Lifelong Learner
A medical technologist’s enduring interest in science and medicine
has fostered a long career of healing and helping.
By Lynda McDaniel

L

ike most high school students in her hometown of Mars Hill, Maine, Lynn
Bray, M.S. ’01, kept an eye on fashion and the Central Aroostook basketball
games. But unlike most of her friends, she enjoyed examining the frogs and
earthworms in the dissection lab. Later, she jumped at the chance to watch
an autopsy while majoring in medical technology at the University of Maine.
“A group of us went to the morgue at the Eastern Maine Medical Center in Bangor,”
Mrs. Bray recalls, chuckling over a favorite story. “The seminary students all left
after one minute. The medical-tech students had their heads right down in it. For
as long as I can remember, I’ve been interested in science and medical issues.”
After graduating Phi Beta Kappa, Mrs. Bray began her long and peripatetic career
as a medical technologist, working in labs in Colorado, Maine and Rhode Island,
where she performed testing in chemistry, hematology and microbiology. By the
late 1990s, she was ready to take her career to a new level while her family was
intent on settling down. They moved to Ridgefield, Conn., where her husband, Jim,
accepted a ministerial position.

Back to school
“I looked around at several schools, and New York Medical College had all the
medical sciences of interest to me,” Mrs. Bray says. “I hadn’t been in school in 25
years, so I took two summer classes to see if I could do it again. When I’d come
home and tell Jim what I’d learned, he told me my face would light up.”
It took her four years to complete her master of science degree in pharmacology,
because in addition to her studies, she was juggling family life (she and Jim have
two daughters) and a part-time job with a dermatologist in Ridgefield as a medical
assistant. Mrs. Bray says she couldn’t have done it without the support she got at
home and on campus.
“Jim has always been supportive of me, encouraging me to go back
to school. And the kids got so excited on graduation day,” Mrs.
Bray recalls. “Dr. Stier was my advisor, and he was very helpful,
especially when I was nearing graduation and looking for a job.”
“Lynn is the type of student that program directors love
to work with,” says Charles Stier Jr., Ph.D., associate
professor of pharmacology. “She all but breezed through
the pharmacology program. She was one of only two
pharmacology master’s students in the past 20 years
to finish with a GPA over 3.92, and at graduation she
was given the Graduate Faculty Council’s award for
academic excellence. It gives me great pleasure to
know that she has done so well in her career.”
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Lynn Bray, M.S. ’01

Ask and receive
While reading the Danbury News-Times six years ago, Mrs. Bray noticed
an ad for a clinical trial in Danbury at the Clinical Research Center of
Connecticut. Armed with her latest credentials and resume, she stopped
by the clinic.
“I asked if they were looking for someone with my qualifications, and I’ve
been there ever since,” she says. “I know my master’s degree helped me
get the job. It also helped me understand the pharmacology of the drugs,
their side effects, and the issues that patients deal with.”
The Clinical Research Center performs Phase III clinical trials that could
last anywhere from two weeks to three years. The director is Kenneth
Miller, M.D., who practices rheumatology on site, treating diseases like
rheumatoid arthritis, osteoporosis and fibromyalgia. Most of the trials are
rheumatology related.
Mrs. Bray started as a clinical research coordinator, performing study
visits according to specific protocols. Her job was to obtain informed
consent, take medical histories and vital signs, and provide medication
accountability, data collection and transcription, and query resolution. Last
year, she earned a promotion to site manager/clinical research coordinator
and now oversees the day-to-day operations of the research center.
Mrs. Bray considers the patients’ welfare as her most important task. In
addition to complying with all the FDA regulations—for example, the
Code of Federal Regulations (CFR) or Good Clinical Practices (GCP)—she
focuses on the participants and ensures that they understand what may lie
ahead as they go through a trial.
As site manager, Mrs. Bray oversees as many as 10 studies at once and all
the protocols for each study. It’s a detail-rich job that includes reviewing
all medications at every visit—right down to the aspirin they took last
Tuesday or the vitamin C they swallowed to fend off a cold.
“Even if they stubbed a toe or had a car accident—it’s important that
we know anything that happened to them since we saw them last,”
Mrs. Bray adds. “Then Dr. Miller determines if that occurrence had any
relationship to the drug in the study. We pass this information on to the
pharmaceutical manufacturer so they can develop a list of possible side
effects. Of course, even with 1,000 people in a trial, not every side effect
will come out until the drug is on the market. To the best of our ability,
we record all the side effects from the group we work with.”

R&R from CFR
Mrs. Bray’s life is not all science. She’s close to her family, which is
growing up fast. Sarah, their older daughter, is in her fourth year of
medicine at the University of Pittsburgh. Rebekah is getting her master’s
degree in teaching foreign language at Wake Forest University in North
Carolina. That leaves Mrs. Bray a little more time for reading, especially
mysteries: “My work can be so intense that part of my home routine is to
purposefully seek relaxation.”
At day’s end, the busy pace and the extra work to ensure the most
accurate results are worth it if it helps people live better lives.
“I find it extremely gratifying when patients do well in trials and get relief.
Fibromyalgia patients, for example, are ecstatic. They tell us that we’ve
given them their lives back. They are pain free and can function in ways
they haven’t been able to. That’s a wonderful feeling,” she reveals. p
For those who participate in clinical research studies supervised
by Lynn Bray, her meticulous attention to detail helps keep them
informed and protected.The fact that such clinical trials often lead
to better and more effective treatments is an attractive bonus.
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Milestones
’07
Josh Rubin, M.D. ’07, is an
anesthesiologist at St. Barnabas
Medical Center in Livingston, N.J.

’06
Joshua Quick, M.D. ’06,
completed deployment with the
26th Marine Expeditionary Unit
and has been assigned as a flight
surgeon for the Marine Medium
Tiltrotor Training Squadron 204,
the “Raptors,” as well as for the
Marine Tiltrotor Operational Test
and Evaluation Squadron 22, the
“Argo Nuts.”

Sushma Jois, M.S., ’97, is a
nutritionist for the Kingsland
Dieticians Group in Katy, Tex.
Felix E. Shepard Jr., M.D.
’93, is in a solo urology private
practice in Norton,Va.

the80s

Michael G. Lewis, M.D. ’04,
a graduate of Fifth Pathway
(now called the Pre-Internship
Program), successfully completed
his pediatric residency training
at Nassau University Medical
Center on Long Island. He is
currently practicing pediatrics
at Notchview Pediatrics in
Clifton, N.J.

Renee Kohanski, M.D. ’87,
continues to write columns for
Talkers magazine, while husband
Philip Kohanski, M.D. ’90, is
state champion for Connecticut
pistol matches.

Daryl Sulit, M.D. ’02, has
completed his dermatology
residency at the Naval Medical
Center in San Diego.

the90s
Matthew Deeter, M.D. ’98,
a trauma surgeon and U.S.
Army Major, has been working
with Doctors Without Borders
in Baghdad, Mosul and most
recently, Sri Lanka. Dr. Deeter
and his wife, Kristina Heer
Deeter, M.D. ’98, and their
two daughters will be moving to
Miami when he returns. He plans
to start a surgical critical care
fellowship at Jackson Memorial
Hospital, while his wife practices
pediatric intensive care at Joe
DiMaggio Children’s Hospital.
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By Andrea Kott, M.P.H.

Elaine Klinge Schwartz, M.D.
’90, is an associate professor
of medicine at National Jewish
Health in Denver. Dr. Schwartz’s
clinical responsibilities include
pulmonary and critical care
medicine. She is also involved in
teaching residents and fellows.
Dr. Schwartz is the mother of
four “very beautiful and active
children!”

’04

’02

Keeping Athletesprofessional and recreational
-In Play

Andre A. Konski, M.D. ’84, a
radiation oncologist, is professor
and chairman of the department of radiation oncology at
Wayne State University School of
Medicine in Detroit, and chief of
radiation therapy at the
Karmanos Cancer Center.
Richard Sturm, M.D. ’83, a
board certified ophthalmologist
specializing in glaucoma and
cataract surgery, is a partner at
Ophthalmic Consultants of Long
Island. Dr. Sturm has participated
in the Mission Cataract USA program, offering free cataract surgery
to residents of Long Island.
Jonathan D. Kunis, M.D. ’82,
is in his fourth year as assistant
medical director at Healthcare Connection, a residential
treatment center for chemical
dependence in Tampa.
Dr. Kunis, an addiction medicine
specialist and internist, received
board certification from the
American Board of Addiction
Medicine.

Stephen J. Nicholas, M.D. ’86

S

ince he’s a physician, saving a life probably could be regarded as part of the
job—except that Stephen J. Nicholas, M.D. ’86, was nowhere near his job last
August when he resuscitated a youngster who’d been found nearly drowned,
unconscious and blue.
“He had been under water for several minutes,” Dr. Nicholas said of 12-year-old
Scott Irwin, who hit his head on a jetty while boogie-boarding at a Long Island
beach. “I cleared his airway and resuscitated him for eight to ten minutes before he
responded. I was concerned we’d lose him.” Not only did Dr. Nicholas save Scott’s
life—with his own five children looking on—he also resuscitated Scott’s love for the
ocean by taking the boy for a jet-ski ride a week later.
Opportunities for heroism are rare, and yet Dr. Nicholas seems to have a sixth
sense for them. While jogging in Central Park one day in 1986, shortly after
receiving his M.D. from New York Medical College, he revived a fellow runner who
was having a heart attack. “It was my first day of being a doctor,” he recalls. Since
then, he has demonstrated his heroism dozens of times and in November received
honors at a “Summer of Heroes” event at the Intrepid Sea, Air and Space Museum,
where museum president Bill White and Nassau County Executive Thomas R. Suozzi
commended him for his charitable work in New York City.
It is all part of the job Dr. Nicholas knew he wanted from the time he watched his
father, the late James Nicholas, M.D., operate on the very famous knee of football
star Joe Namath. The elder Dr. Nicholas, a prominent orthopedic surgeon credited
with creating the field of sports medicine, cared for numerous top sports teams,
including the New York Knicks and the New York Rangers. “That’s how I became
interested,” the son says.
It was also his personal love of sports, his fascination with science and the body’s
mechanics, and the satisfaction of restoring an injured patient’s ability to enjoy an active lifestyle that drew him to the specialty more than 20 years ago. “There is something great about taking care of somebody who comes to you with an injury and

wants to return to the way they were.” says the surgeon, who observed
his first knee operation at age five.
Dr. Nicholas talks fast. That could be because he divides his time among
four practice locations and has a lot of ground to cover. He is a renowned
sports medicine specialist—one of New York Magazine’s “Top Doctors” for
the past 10 years who has served as team doctor for the New York Jets,
New Jersey Gladiators, New York Islanders, and professional roller hockey
teams. He is also a recreational athlete who played football, baseball,
hockey and basketball in college.
A native New Yorker, Dr. Nicholas earned his undergraduate degree from
Harvard University. After medical school, he completed a residency in
orthopedic surgery at the Hospital for Special Surgery and a fellowship in
sports medicine at Lenox Hill Hospital, both in Manhattan. He has
received numerous honors, including a spot in the National Football Foundation and College Hall of Fame. Founder and director of NY
Orthopedics, Dr. Nicholas also directs the Nicholas Institute of Sports
Medicine and Athletic Trauma at Lenox Hill.
There is no denying the thrill of caring for the high-profile bones and joints
of a New York Jet. “Seeing an NFL running back run 1,500 yards or throw a
ball 60 yards … you know you’ve done everything you possibly can when
you see an athlete return to a high level of function,” he says. At the same
time, there is no missing Dr. Nicholas’ fierce commitment to helping average
recreational athletes maintain their active lifestyles. “What about the 60-yearold who likes to play tennis three days a week?” he points out.
“Athletics is something we want everybody to do,” he continues. “If they’re
not able to do it because of some injury or defect in their body, it’s up to
us to help them maintain their quality of life.”
Passionate as he is about sports medicine, however, Dr. Nicholas voices
concern about the patients needing it most these days: school-age athletes.
The growth of year-round, school-based team sports, along with a move
toward encouraging youngsters to specialize and compete in a single
sport, have increased the incidence of repetitive, potentially debilitating
injuries at earlier ages.
Kids who play baseball year-round, for example, are throwing the ball
more and suffering more overuse of arm muscles and ligaments because
their bodies don’t have time to heal, Dr. Nicholas laments. “Parents are
coming in and asking to have their children operated on at an early age
because they want their kids to become professional athletes,” he says.
“They want the Tommy John procedure so their kids can throw farther,”
describing an operation named for a Los Angeles Dodgers pitcher. The
surgery reconstructs the ulnar collateral ligament (UCL) by using a tendon
from the forearm to improve the stability of the elbow joint.
“We’re operating on these kids at a much younger age than we used to,”
Dr. Nicholas says. “Fitness at an earlier stage is great, but specialization is
beginning to take its toll.” So, as he cares for younger and younger athletes,
he also urges them to train in a variety of sports and athletic activities so
they can stay active, and uninjured, longer.
The ultimate goal for this doctor-athlete is to keep his patients, whether
amateurs or pros, on the field: “ When they come back into the office for
a checkup five months after I’ve fixed them—that’s a tremendous sense of
satisfaction.”p

Brian Solow, M.D. ’82,
is medical director for
Prescription Solutions, a
national pharmacy benefit
manager headquartered in
Irvine, Calif.

William C. Reha, M.D. ’81,
M.B.A., was honored with
the 2009 Clarence A. Holland
Award, presented annually to a
Virginia physician for outstanding contributions promoting the
art and science of medicine and
the betterment of public health
through political service.

Alan J. Conrad, M.D. ’81,
an internist with the North
County Internists Medical
Corporation in Poway, Calif.,
received his master’s degree
in medical management
from the Marshall School of
Business at the University of
Southern California.

Lisa Borg, M.D. ’80, board certified in psychiatry and addiction
psychiatry, is a senior research
associate and associate attending
physician at the Rockefeller University in the Laboratory of the
Biology of Addictive Diseases. Dr.
Borg’s areas of interest include
the clinical neurobiology and genetics of addictive diseases. She
is also clinical assistant professor
on the voluntary faculty at Weill
Cornell Medical School. Dr. Borg
maintains a private practice on
the Upper East Side of Manhattan. She has three children.

Charles Paidas, M.D. ’81,
is dean for graduate medical
education and executive
associate dean for clinical and extramural affairs
at the University of South
Florida College of Medicine
in Tampa.

(continued on next page)

Judith M. Watson, M.P.H. ’07
(continued from page 25)

“This is my biggest disappointment professionally,” Watson says.
“We spent years convincing people why we had to move forward
and now the budget is all but out of reach.”
However, under the American Recovery and Reinvestment Act
(ARRA) of 2009, otherwise known as the government stimulus
package, funds are being made available to a limited number of
community health centers for expansion of services and infrastructure. Greenburgh has applied for a share of those funds to help
them build their new center. “It’s a long shot, but if we get it, it
will be a major victory,” Watson says. [At press time, she still had
not heard the results of her application.]
Despite the many demands and pressures of her job, Watson
says she couldn’t see herself doing anything else. When she’s not
working, she’s usually jogging or spending time with friends and
her large, close-knit family, including 6-year old niece Dream,
whom Watson calls “the light of my life.”
While it’s easy to become frustrated over the complex and problematic state of health care today, Watson says working at the
Greenburgh Health Center satisfies her core belief that everyone
is entitled to the same basic medical services. “Health care is the
right of every human being,” she asserts. “The fact that I’m part of
an organization that makes that possible, that alone fulfills me.”p
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Retirement Means
having more time for
Grandchildren and Theater
By Andrea Kott, M.P.H.

W

hen we last met Joan Liman (Chironian
Spring/Summer 2005), her plate was
already full. She was working as assistant dean and deputy to the medical director at
Metropolitan Hospital Center, she was volunteering
for Amas, a non-profit, multi-ethnic theatrical organization, and she was not quite five years along in her
recovery from a mastectomy and chemotherapy for
Stage 3 breast cancer. It was her second bout with
cancer in 20 years—she was treated for Stage 4
non-Hodgkin’s lymphoma in 1981.

Joan P. Liman, M.D. ’83,
M.P.H. ’93

An indefatigable survivor, Dr. Liman has a plate that
is fuller than ever. Now retired from Metropolitan
and the College, she has become president of Amas,
as well as an occasional co-producer. She is the
engine behind LimanAde Productions, a fundraising
venture that features readings of original works at
her New York City apartment. Rounding out her
involvement in the arts, she works as a docent for
the Museum of Jewish Heritage in Battery Park.
Oh, and one more, very important thing. She is a
new grandmother.

“Ryan Levi Gottlieb was born June 10, 2008,” Dr.
Liman says, heading off the question. Grandmotherhood moved Dr. Liman to retire more
than a year ago, and when she is not visiting Ryan,
she is co-producing one of Amas’ upcoming
productions. Signs of Life: A Tale of Terezin is a play
about life in Theresienstadt, a Jewish ghetto set
up by the Nazis in the former Czechoslovakia.
“Theresienstadt, or Terezin in Czech, was where
they gathered many Jews with an artistic bent,”
Dr. Liman said, explaining how the Nazis forced
prisoners to produce shows to convince the
public that it was merely an artist’s colony.
The play originated nine years ago after its
commercial producer, Virginia Criste, learned
that her grandparents were on the last transport
from Theresienstadt to Auschwitz, where they
perished. When Criste initially visited
Theresienstadt in the early 1990s, she found a
makeshift museum with inhabitants’ art hanging
on the walls and rows of bulletin boards with
exhibits of tickets and programs from
performances. Criste envisioned a theater lobby
filled with Theresienstadt remnants and that
became the genesis for the show.
“This is a beautiful piece of theater and a story
that must be told,” Dr. Liman said. “There is a
generation of school children and, sadly, adults

Milestones
(continued from page 29)

the70s
Pearl I. Steinmetz-Herskovitz, M.D. ’79, is director of
the CT unit at Kaplan Hospital
in Rehovot, Israel, where she
has been living since 1986. Dr.
Herskovitz’s oldest son,Yaakov,
is studying for his master’s in
Hebrew literature at Hebrew
University in Jerusalem. Her
second son, Netanel, who was
injured in a suicide bomber
attack in 2001, has been studying occupational therapy at Haifa
University. Her daughter Re’ut
(which means “comradeship”) is
in sixth grade.
Jennifer Thulin, M.D. ’79,
has been working in a private
gynecology practice in the
Boston suburbs for more than
25 years and would welcome
any contact from classmates.
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Philip A. Kern, M.D. ’78, is
director of the BarnstableBrown Diabetes and Obesity
Center at the University of
Kentucky College of
Medicine in Lexington.
Robert Broderick, M.D.
’77, is an attending ophthalmologist at St. Francis Hospital and Island Eye Surgicenter
and a partner at Ophthalmic
Consultants of Long Island.
Dr. Broderick participates in
the Mission Cataract USA
program, which offers free
cataract surgery to residents
of Long Island who cannot
afford the surgery. Dr.
Broderick is also on the
Board of the American
College of Surgeons
Credentialing Committee,
is a Fellow of the American
Academy of Ophthalmology,
the American College of

Surgeons, and is a member of
the American Society of Cataract and Refractive Surgery.
Scott Cutler, M.D. ’77, is in
his 28th year as a private practice, adult clinical psychiatrist
in Worcester, Mass., and recently opened a second office
in New York City. Dr. Cutler
writes that daughter, Beth
Cutler, M.D. ’06, is starting
her fourth year of a general
surgical residency at St. Luke’sRoosevelt Hospital Center.
Maxine S. Jochelson, M.D.
’77, a board-certified diagnostic radiologist, is director of
radiology for the new breast
and imaging center at Memorial Sloan-Kettering Cancer
Center in New York City. Dr.
Jochelson completed her residency at Los Angeles County
Hospital-USC Medical Center

and a fellowship at the Dana
Farber Cancer Institute.
Prior to joining the MSKCC
faculty, she was an attending
radiologist at Tarzana Medical
Center in California, and codirector of the San Fernando
Valley Women’s Center.
Barry S. Leitman, M.D.
’75, is a professor of
radiology at NYU School of
Medicine and NYU Medical
Center. Recently inducted
as a Fellow of the American
College of Radiology, Dr.
Leitman also belongs to the
Radiological Society of North
America, American Roentgen
Ray Society, and the Society
of Thoracic Radiology.
Jack Albert, M.D. ’74,
writes that daughter Amanda
earned her master’s degree
in piano performance at

who do not know the history of the Holocaust.” A limited engagement of the
play is scheduled for February at the Marjorie Deane Little Theatre, located at the
West Side Y on West 63rd Street in Manhattan.
In addition to becoming a co-producer, Dr. Liman is now a first-time composer,
having written a quasi-autobiographical musical, A LimanAde Life. A self-described
“frustrated lyricist” who says she is neither an author nor a composer (“I can
play by ear and plunk it on the piano!”), she began in 2001 by setting original
lyrics about her battles with cancer and depression to Broadway show tunes.
She paired “Lymphoma” with the music of the title song from Oklahoma and
“Depression” to the melody of “Tradition” from Fiddler on the Roof.
While ditties about cancer and mental illness may seem like unlikely
entertainment, Dr. Liman knew she’d have an audience. “One of the reasons I
think I’m alive today is because of my sense of humor,” she said. “In addition to
having excellent medical care…maintaining a sense of humor was equally
important to my medical regimen.”
The two-act play has received glowing reviews from small audiences at
Metropolitan Hospital and Hope Lodge, an American Cancer Society-funded
temporary housing facility for cancer patients and their caregivers.
As for her health, Dr. Liman, 60, just received a clean bill, and she’s not letting any
grass grow under her feet. In addition to her artistic and family pursuits, she is
a legislative ambassador for the American Cancer Society. She also works with
MetPALS, a program she started at Metropolitan Hospital, which teaches minority
or underserved New York City youth about careers in medicine and health care
by taking them on field trips and introducing them to healthcare professionals.
It is a busy life, but Joan Liman learned long ago that lots of laughter and
meaningful work are essential ingredients for health and happiness—after her
grandson, of course. p

In Memoriam
Mitchell L. Goldbaum, M.D. ’87,
died August 8, 2008.

Norman Chu, M.D. ’51, died
October 22, 2008.

Dwight M. Pagano, M.D. ’78, died
July 1, 2009. He was 57.

Benjamin Nicotri, M.D. ’50, died
July 30, 2009. He was 90.

Steven B.Tamarin, M.D. ’77 (Fifth
Pathway), died November 30, 2008.
He was 61.

Edward A. Clerkin, M.D. ’48,
died June 25, 2009. He was 85.

Jeffrey Behrens, M.D. ’76, died June
9, 2009. He was 57.
Allan Jacobs, M.D. ’69, died August
29, 2008.
Patrick J. Dwyer, M.D. ’66, died
August 12, 2009. He was 70.

David J. Beccia, M.D. ’70, is
celebrating 32 years of practice
in urology in Bay Shore, N.Y.,
“and still going strong!” Dr.
Beccia is also celebrating 41
years of marriage to Jessica,
and the arrival of their first
grandchild, Anna, “who is the
love of our life.”

the60s
Alan Wecksell, M.D. ’65,
retired in September 2009.
Nicola Bitetto, M.D. ’64,
retired in June 2009.

Michael Schlossberg, M.D.
’62, retired in 2001 after
practicing ob-gyn for many
years. Dr. Schlossberg and wife
Lana spend their time enjoying
their children and grandchildren, traveling and collecting
and studying art.
Robert Kirschner, M.D. ’61,
is retired and living in New
York City.

the50s
Justin Howland, M.D. ’59,
has published a book, A California Bonesetter’s Autobiography,
in which he mentions certain

James B. Lynch, M.D. ’47, died
June 25, 2009. He was 86.

Marvin A. Humphrey, M.D. ’43,
died July 22, 2009.

Arthur J. Grahl, M.D. ’61, died
December 17, 2008.
Allen F. Langhorne, M.D. ’61, died
July 28, 2009. He was 82.
Kenneth M.Young, M.D. ’61, died
October 21, 2008. He was 74.
Richard A. Giery, M.D. ’60, died
August 5, 2008.

Joseph B. Enders, M.D. ’41, died
September 18, 2009.
Joseph Sarullo, M.D. ’41, died
May 28, 2009. He was 95.
Roger D. Sherman, M.D. ’40,
died May 15, 2009. He was 93.
Charles P.Vialotti, M.D. ’36, died
February 24, 2009.

Buck J. Williams, M.D. ’60, died
July 2, 2009. He was 74.
John M. Marino, M.D. ’59, died July
9, 2009. He was 75.

James A. Holleran, M.D. ’56, died
May 31, 2009. He was 78,

Stephen M. Brenner, M.D.
’62, is still practicing medicine
in the Bronx. He is father to
three adult children, grandfather to nine, and “enjoying
it all.”

Robert M. Ahrens, Sr., M.D. ’47,
died February 24, 2008.

Robert S. Bailey, M.D. ’43, died
October 21, 2009. He was 93.

Jaime Olivo, M.D. ’64, died
October 15, 2009. He was 70.

Roland K. Molinet, M.D. ’59, died
August 8, 2009. He was 76.

Northwestern University and
is in her first year of a doctoral
program at the University of
Houston. Son Josh, an 11thgrader, is a top percussionist at
Spruce Creek High School in
Port Orange, Fla.

Miguel A. Figueroa, M.D. ’48,
died May 25, 2009. He was 86.

William H. Nass, M.D. ’56, died
September 16, 2009.

Faculty
Sidney Berezin, M.D., clinical
assistant professor of pediatrics, died
in October 2009. He was the father
of Stuart H. Berezin, M.D., associate
professor of pediatrics and chief
of pediatric gastroenterology at
Westchester Medical Center.
John F. Gillooley, M.D., clinical
associate professor of pathology
who retired as chairman of
Pathology at St. Vincent’s Hospital,
Manhattan, died in June, 2009.
Among many achievements, he
pioneered histologic grades in the
prognosis of breast cancer, and was
one of the first practitioners at the
beginning of the AIDS epidemic to
recognize the significance of Kaposi’s
sarcoma in diagnosing the disease.

Lawrence A. Norton, M.D. ’56,
died May 13, 2009. He was 78.
Ernest J. Petrulio, M.D. ’55, died
October 20, 2008. He was 80.
Melvin A. Scharfman, M.D. ’54,
died October 18, 2008. He was 80.
John H. Small, M.D. ’54, died July
29, 2009.
Richard McManus, M.D. ’53, died
August 18, 2009. He was 81.

Board of Trustees

Norman M. Brust, M.D. ’51, died
July 26, 2009. He was 86.

Patricia Mosbacher, honorary
trustee, died in February 2009.

classmates, along with two
instructors, Dr. Minervini and
Dr. Stanley Opler, the latter of
whom was his employer while
working at Lenox Hill Hospital.
Howard Kline, M.D. ’58,
is still in active practice as a

cardiology consultant in San
Francisco and heavily involved in teaching cardiology
to house staff and cardiology
fellows. Dr. Kline reports that
son Christopher is starting
his fourth year of medical
school at the College. p
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Alumni
Association
Board of
Governors
Officers
President
Eileen (Lee) M. Dieck, M.D. ’86

Sesquicentennial Dinner
At the Sesquicentennial Dinner, held October 17, 2009, at Glen Harbour Island
in New Rochelle, N.Y., the College’s 150th anniversary celebration was formally
launched.The honoree was the College itself—its students, faculty, alumni and
staff—and guests enjoyed a short video depicting the College’s illustrious history.

President Elect
Mario F. Tagliagambe Jr., M.D.’84
Vice President
Charles W. Episalla, M.D. ’88
Treasurer
Stephen J. Nicholas, M.D. ’86
Archivist
Robert J. Furey, M.D. ’62

1.

2.

3.

Elected Governors
John R. Addrizzo, M.D. ’64
Thomas D. Cerabona, M.D. ’82
John M. Cosgrove, M.D. ’83
Caroline A. Fierro, M.D. ’95
Joseph L. Giamelli, M.D. ’02
Jane N. Haher, M.D. ’67
Henry I. Saphier, M.D. ’61
George C. Shapiro, M.D. ’88
Faculty Governor
Leonard J. Newman, M.D. ’70
Past Presidents
Dennis J. Allendorf, M.D. ’70
Michael A. Antonelle, M.D. ’62
Saverio S. Bentivegna, M.D. ’50
Joseph F. Dursi, M.D. ’59
Louis E. Fierro, M.D. ’60
Rita F. Girolamo, M.D. ’51*
Cyrille H. Halkin, M.D. ’45*
Henry P. Leis Jr., M.D. ’41*
David T. Mininberg, M.D. ’61
E. Edward Napp, M.D. ’33*
Christopher F.X. Riegler, M.D. ’88
Seymour Schlussel, M.D. ’51*
Lawrence B. Slobody, M.D. ’36*
Martin L. Stone, M.D. ’44
Paul Tartell, M.D. ’52*
Member Emeritus
Philip A. Marraccini, M.D. ’50
Vice President,
Development and
Alumni Relations
Julie A. Kubaska, M.S.
(*) Deceased
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4.

6.

5.

7.

8.

Photos by John Vecchiolla

Leading Edge
(continued from page 16)
of weight gain, waist gain and white-coat hypertension
in women and its role as an alphabetic and chronologic
antecedent to the better known Syndrome X.
In conjunction with colleagues at Montefiore Medical
Center and the University of Tennessee (Memphis),
Dr. Mogul is conducting a multicenter study that targets
women with Syndrome W. This double blind, placebo
controlled, randomized clinical trial evaluates efficacy and
safety of metformin—a diabetes drug known to
decrease insulin resistance and promote weight loss
—and metformin plus low dose rosiglitazone (another
diabetes medication) as an adjunct to a carbohydrate
modified diet and behavioral strategies. Participants

attended weekly nutrition workshops where they were
introduced to the EMPOWIR dietary intervention.
Data from 49 subjects were presented at the annual
meeting of The Obesity Society in October, 2009. Changes
in body weight were significant and comparable at two
study sites. Earlier research supports hypotheses that
insulin elevation could be a cause, as well as a
consequence, of weight gain, accounting for progressive
and intractable menopausal weight gain.
“EMPOWIR: Enhance the Metabolic Profile
of Women with Insulin Resistance.” Poster
presented at the annual meeting of The Obesity Society,
October, 2009. p

Celebration
1. William Dieck, M.D., Eileen M. Dieck, M.D. ’86, met
up with Patricia Barry, M.D. ’83, and John Cosgrove,
M.D. ’83.
2. A special award was given to Saverio S. Bentivegna,
M.D. ’50. He was joined by his wife Kathleen, and
Ingrid Connolly.
3. Enjoying the gala were Assemblywoman Amy Paulin
and Ronald F. Poe, chairman of the Board of Trustees.
4. Among the more than 400 guests at the black tie
celebration dinner were David Asprinio, M.D.,
chairman of orthopedic surgery, and Matthew
Harris, M.D.
9.

10.

5. R
 obert W. Amler, M.D., dean of the School of Health
Sciences and Practice, shared a laugh with New York
State Senator Suzi Oppenheimer, Karl P. Adler, M.D.,
president and CEO, and Mr. Poe.
6. D
 rs. Adler and Amler accepted a proclamation
presented by New York State Senator Andrea
Stewart-Cousins.
7. D
 r. Adler presented a plaque to Dr. Lee Dieck,
Alumni Association President.
8. Graduate School of Basic Medical Sciences Dean
Francis L. Belloni, Ph.D., enjoyed a dance with his
wife, Margaret Ciarcia.

11.

12.

9. John Fallon III, M.D., Ph.D., chairman of pathology,
and his wife Mary chatted with William H. Frishman,
M.D., professor and chairman of medicine, and
his wife Esther.

13.

10. Ralph A. O’Connell, M.D., provost and dean of the
School of Medicine, and Dr. Adler surveyed the
lively scene.
11. Joseph F. Dursi, M.D. ’59, served as Master
of Ceremonies.
12. Michael A. Antonelle, M.D. ’62, greeted Samuel H.
Rubin, M.D., provost and dean emeritus.
14.

13. Dr. Adler accepted an official proclamation from
Westchester County Executive Andrew J. Spano.

15.

14. Among the guests were College trustee Maureen
Roxe and her husband Joe Roxe of Darien.
15. Sen. Oppenheimer and her husband Martin J.
Oppenheimer chatted with Dean Amler and Sherlita
Amler, M.D., Putnam County Health Commissioner,
who is also a faculty member.

16.

17.

16. Dr. John Connolly, former president of New York
Medical College, and his wife Ingrid, far left, chatted
with Jane O’Connell.
17. Joseph Giamelli, M.D.’02, and his wife Anna enjoyed
the dancing with their daughter Samantha.
18. Joining the festivities were Edmund F. LaGamma, M.D.
’76, and his wife Kalliope.
19. Representing the university’s three schools were
students Obiageli Nwankwo (Health Sciences and
Practice), Candace Ford (Basic Sciences) and Stephen
Rotman (Medicine).

18.

19.
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